SECOR Capital Advisors LP Invests $728,000 in Cambrex Corporation (CBM)
SECOR Capital Advisors LP acquired a new position in shares of Cambrex Corporation (NYSE:CBM) during the third quarter, Holdings Channel reports. The firm acquired 16,368 shares of the company’s stock, valued at approximately $728,000. SECOR Capital Advisors LP owned approximately 0.05% of Cambrex Corporation as of its most recent filing with the SEC.
Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC bought a new position in Cambrex Corporation during the second quarter worth about $106,000. BlackRock Inc. raised its position in Cambrex Corporation by 38.6% in the second quarter. BlackRock Inc. now owns 2,855 shares of the company’s stock worth $149,000 after buying an additional 795 shares in the last quarter. PineBridge Investments L.P. raised its position in Cambrex Corporation by 4.4% in the second quarter. PineBridge Investments L.P. now owns 4,056 shares of the company’s stock worth $210,000 after buying an additional 171 shares in the last quarter. Advisors Asset Management Inc. bought a new position in Cambrex Corporation during the second quarter worth about $216,000. Finally, Teacher Retirement System of Texas raised its position in Cambrex Corporation by 13.7% in the second quarter. Teacher Retirement System of Texas now owns 4,413 shares of the company’s stock worth $228,000 after buying an additional 533 shares in the last quarter. Institutional investors and hedge funds own 98.71% of the company’s stock.
Shares of Cambrex Corporation (NYSE:CBM) traded up 1.18% on Friday, reaching $55.85. The company’s stock had a trading volume of 162,663 shares. The stock has a 50-day moving average of $53.35 and a 200 day moving average of $48.86. Cambrex Corporation has a 52 week low of $29.50 and a 52 week high of $59.41. The stock has a market capitalization of $1.80 billion, a price-to-earnings ratio of 29.49 and a beta of 1.95.
Cambrex Corporation (NYSE:CBM) last released its quarterly earnings results on Friday, November 4th. The company reported $0.47 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.41 by $0.06. Cambrex Corporation had a return on equity of 24.11% and a net margin of 13.24%. The firm had revenue of $99.90 million for the quarter, compared to the consensus estimate of $96.07 million. During the same quarter last year, the business posted $0.40 EPS. The company’s revenue for the quarter was up 8.2% on a year-over-year basis. On average, analysts expect that Cambrex Corporation will post $2.70 EPS for the current year.
A number of research firms recently issued reports on CBM. Zacks Investment Research upgraded Cambrex Corporation from a “hold” rating to a “strong-buy” rating and set a $53.00 price objective for the company in a research report on Monday, November 7th. First Analysis upgraded Cambrex Corporation from an “equal weight” rating to an “overweight” rating and set a $54.00 price objective for the company in a research report on Monday, November 7th.
In other Cambrex Corporation news, insider Gregory Sargen sold 22,500 shares of Cambrex Corporation stock in a transaction dated Friday, November 11th. The stock was sold at an average price of $52.02, for a total value of $1,170,450.00. Following the sale, the insider now owns 27,500 shares of the company’s stock, valued at approximately $1,430,550. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Shawn Cavanagh sold 30,000 shares of Cambrex Corporation stock in a transaction dated Wednesday, December 14th. The shares were sold at an average price of $53.58, for a total value of $1,607,400.00. Following the completion of the sale, the chief operating officer now directly owns 27,658 shares in the company, valued at approximately $1,481,915.64. The disclosure for this sale can be found here. 2.63% of the stock is owned by company insiders.
Cambrex Corporation Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. The Company provides products and services for the development and commercialization of new and generic therapeutics. The Company supplies its products and services across the world to generic pharmaceutical companies. Cambrex operates through three segments, which are manufacturing facilities.
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Corporation (NYSE:CBM).
Receive News & Ratings for Cambrex Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex Corporation and related companies with MarketBeat.com's FREE daily email newsletter.